OTHER
GIP receptor antagonist
GIP receptor antagonist
Status
Completed
Phase
Not applicable
Enrollment
8
Locations
2
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.
Full detailed description
Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects. Six study hyperglycemic clamps (10 mmol/l) pr. participant.
Interventions
Treatment arms and agents.
OTHER
GIP receptor agonist
GIP(1-42)
OTHER
Saline
Placebo (vehicle for infusions)
Timeline
From registration to results.
First posted
Dec 10, 2018
Study start
Dec 6, 2018
Primary completion
Mar 1, 2019
Study completion
Dec 1, 2019
Results posted
Not reported
Registry updated
Mar 26, 2020
Outcomes
What the study measures.
Primary outcomes
Insulin secretion
Time frame · 8 weeks
Insulin secretion rates (ISR) calculated from serum levels of C-peptide
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Sex
- MALE
- Healthy volunteers
- Yes
Inclusion Criteria: * Healthy * BMI 19-28 kg/m\*m * Stable body weight Exclusion Criteria: * Diabetes * Anemia * First-degree relatives with diabetes
Study locations
2 registered sites.
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Clinical Metabolic Physiology
Gentofte Municipality, Copenhagen, Denmark
Clinical Metabolic Physiology
Copenhagen, Gentofte, Denmark
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Secretin.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
Mayo Clinic · Exocrine Pancreatic Insufficiency · Chronic Pancreatitis
Phase 4
Recruiting
24
2026-07
Secretin in Ex-situ Liver Perfusion
Erasmus Medical Center · Liver Transplantation
Phase 1 / Phase 2
Enrolling by invitation
20
2026-06
Imaging Biomarkers of Pancreatic Function and Disease
Children's Hospital Medical Center, Cincinnati · Pancreatitis · Diabetes Mellitus
Phase 4
Enrolling by invitation
195
2026-03
Secretin in Refeeding
University of California, Los Angeles · Anorexia in Adolescence
Not applicable
Recruiting
10
2026-02
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
M.D. Anderson Cancer Center · Pancreatitis
Not applicable
Recruiting
2,345
2025-10
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University · Pancreas Cancer · Peutz-Jeghers Syndrome (PJS)
Phase 3
Recruiting
9,000
2025-10
The Effects of Bariatric Surgeries on Glucose Metabolism
The University of Texas Health Science Center at San Antonio · Post Bariatric Surgery · Gastric Bypass
Early Phase 1
Recruiting
200
2025-09
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Adenocyte, LLC · IPMN, Pancreatic · Pancreas Cancer
Not applicable
Enrolling by invitation
500
2025-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.